Antithrombotic and thrombolytic therapy for ischemic stroke

Journal of Thrombosis and Thrombolysis

Volumn 7, Issue 2, 1999, Pages 165-169

  Fisher, Marc ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b Memorial Health Care   (United States)

Author keywords

Antithrombotic therapy; Stroke; Thrombolysis

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; ANTICOAGULANT AGENT; CLOPIDOGREL; DIPYRIDAMOLE; HEPARIN; TICLOPIDINE;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL TRIAL; DIARRHEA; FIBRINOLYTIC THERAPY; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RASH; SHORT SURVEY; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION; VEIN THROMBOSIS;

ASPIRIN; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; FIBRINOLYTIC AGENTS; HUMANS; ISCHEMIC ATTACK, TRANSIENT; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES; QUALITY ASSURANCE, HEALTH CARE; THROMBOLYTIC THERAPY;

EID: 0032962905     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008889605137     Document Type: Short Survey

References (24)

1. The Canadian Cooperative stroke. N Engl J Med 1978; 299:53-59.
2. Antiplatelet Trialists' Collaboration. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308:81-106.
3. Barnett HJM, Eliasziw M, Meldrum HE. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med 1995;332:238-248.
4. UK-TIA Study Group. The United Kingdom transient ischemic attack (UK-TIA) aspirin trial; final results. J Neurol Neurosurg Psych 1991;54:325-334.
5. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991;325:1261-1266.
6. The SALT Collaborators Group. Swedish low-dose trial of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991;338:1345-1349.
7. The ESPS Group. European Stroke Prevention Study. Stroke 1990;211:1122-1130.
8. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1995;143:1-13.
9. Gent M, Blakely JA, Easton JD, et al. The Canadian-American ticlopidine study (CATS) in thromboembolic stroke. Lance 1989;1:1215-1220.
10. Hass WK, Easton JD, Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989;321:501-507.
11. Caprie Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329-1339.
12. Genton E, Barnett HJM, Fields WJ, Lent M, Hoak JC. Cerebral ischemia: The role of thrombosis and of antithrombotic therapy. Stroke 1977;8:150-175.
13. Marsh EE, Adams HP, Biller J, et al. Use of antithrombotic drugs in the treatment of acute ischemic stroke: A survey of neurologists in practice in the United States. Neurology 1989;39:1631-1634.
14. Duke RJ, Bloch RF, Turpie AGG, Trebilcock R, Bayer N. Intravenous heparin for the prevention of stroke progression in acute partial stable stroke. Ann Intern Med 1986;105:825-828.
15. International Stroke Trial Collaborative Group. The International Stroke Trial (IST): A randomized trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997;349: 1569-1581.
16. Kay R, Wong KS, Ling Y, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995;333:1588-1593.
17. Trial of Org10172 in acute stroke treatment. Presented at the 6th European Stroke Conference, Amsterdam, May 1997.
18. CAST (Chinese Acute Stroke Trial) Collaborative Group. CAST: randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997;349:1641-1649.
19. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
20. Hacke W, Kaste M, Fieschi, C, et al. for The ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA 1995;274:1017-1025.
21. Donnan GA, Davis SM, Chambers BR, et al. for the Australian Streptokinase (ASK) Trial Study Group. Streptokinase for acute ischemic stroke with relationship to time of administration. JAMA 1996;276:961-966.
22. Multicenter Acute Stroke Trial-Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med 1996;335:145-150.
23. Multicenter Acute Stroke Trial-Italy (MAST-I) Group. Randomized controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet 1995;346:1509-1514.
24. Del Zoppo GJ, Higashida RT, Furlan AJ, et al. The Prolyse in Acute Cerebral Thromboembolism Trial (PROACT); results of 6 mg dose tier. Stroke 1996;27:164.